Specifically, RACGAP1 silencing markedly reduced the tumor weight and volume (Fig. 3E-G) as well as the expression of proliferation marker Ki67 (Fig. 3H-I) of the tumor-bearing mice, while such anti-tumor effects of RACGAP1 silencing were partly counteracted by ferroptosis inhibitor ferrostatin-1 treatment. Here, MKI67 is linked to neoplasm.